搜尋結果
For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Do
The Wall Street Journal· 6 日前In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease< ...
Annovis tumbles as Alzheimer's treatment misses in mid-stage study
Reuters· 2 日前The trial tested the drug buntanetap in patients with mild-to-moderate Alzheimer'& ...
Oasis Or Mirage? Digital Dementia Screening In The Neurology Desert
Forbes· 6 日前In my neurotech travels the most common companies I encounter are those building digital dementia screening tools. The number ...
GE Healthcare's disappointing first quarter offers both a lesson and an opportunity
CNBC· 1 日前GE Healthcare shares sank Tuesday after the company's first-quarter sales and profits fell ...
Council Post: AI Can ‘Unbias’ Healthcare—But Only If We Work Together To End Data Disparity
Forbes· 6 日前The excitement around AI’s potential to solve healthcare’s biggest problems is palpable ... ...
neuroClues wants to put high-speed eye-tracking tech in the doctor's office
TechCrunch· 1 日前It wants to make it easier for healthcare service providers to use eye tracking to support the ...
A Predictive Healthcare Visionary Is Optimistic About Solving America’s Opioid Addiction And ...
Forbes· 6 日前“Chronic pain,” the CDC said,” ...is a debilitating condition that affects daily work and life ...
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
CNBC· 1 日前The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes ...